➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Merck
Moodys
Mallinckrodt

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

PENTETATE CALCIUM TRISODIUM Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Pentetate Calcium Trisodium patents expire, and what generic alternatives are available?

Pentetate Calcium Trisodium is a drug marketed by Hameln Pharma Plus and is included in one NDA.

The generic ingredient in PENTETATE CALCIUM TRISODIUM is pentetate calcium trisodium. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pentetate calcium trisodium profile page.

US ANDA Litigation and Generic Entry Outlook for Pentetate Calcium Trisodium

A generic version of PENTETATE CALCIUM TRISODIUM was approved as pentetate calcium trisodium by HAMELN PHARMA PLUS on August 11th, 2004.

  Start Trial

Summary for PENTETATE CALCIUM TRISODIUM
Drug patent expirations by year for PENTETATE CALCIUM TRISODIUM
Recent Clinical Trials for PENTETATE CALCIUM TRISODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1/Phase 2

See all PENTETATE CALCIUM TRISODIUM clinical trials

Pharmacology for PENTETATE CALCIUM TRISODIUM
Drug ClassLead Chelator
Mechanism of ActionLead Chelating Activity

US Patents and Regulatory Information for PENTETATE CALCIUM TRISODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hameln Pharma Plus PENTETATE CALCIUM TRISODIUM pentetate calcium trisodium SOLUTION;INHALATION, INTRAVENOUS 021749-001 Aug 11, 2004 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Moodys
Merck
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.